Core Points - Bluejay Diagnostics, Inc. has completed a private placement of 2,250,000 shares of common stock and Series F warrants to purchase up to 4,500,000 shares at a price of $2.00 per share, with Series F warrants having an exercise price of $1.75 and expiring in five and a half years [1][2] - The gross proceeds from this offering amounted to $4.5 million, which will be used for FDA approval processes, clinical studies, research and development, and general working capital needs [2] - The securities were offered under Section 4(a)(2) of the Securities Act and have not been registered, meaning they cannot be sold in the U.S. without an effective registration statement or applicable exemption [3] Company Overview - Bluejay Diagnostics focuses on improving patient outcomes through its Symphony System, a rapid near-patient testing system for sepsis triage and disease monitoring [5] - The company's first product candidate is an IL-6 Test for sepsis, designed to deliver accurate results in approximately 20 minutes, aiding medical professionals in making timely treatment decisions [5]

Core Viewpoint - Bluejay Diagnostics, Inc. has announced a private placement of common stock and Series F warrants to raise approximately $4.5 million to fund FDA approval processes and other R&D activities [1][2]. Group 1: Offering Details - The company will sell 2,250,000 shares of common stock at a price of $2.00 per share, along with Series F warrants to purchase up to 4,500,000 additional shares at an exercise price of $1.75 [1]. - The Series F warrants will be exercisable immediately and will expire 5.5 years from the issuance date [1]. - The private placement is expected to close on or about October 10, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for obtaining FDA approval, including related clinical studies, as well as for general working capital and other research and development activities [2]. Group 3: Company Overview - Bluejay Diagnostics focuses on improving patient outcomes with its Symphony System, a rapid near-patient testing system for sepsis triage and disease monitoring [5]. - The company's first product candidate is an IL-6 Test for sepsis, designed to deliver results in approximately 20 minutes, aiding medical professionals in making timely treatment decisions [5].

Core Insights - Bluejay Diagnostics, Inc. provided a mid-year business update for 2025, highlighting progress in its clinical programs and financial status [1][2] Business Highlights and Developments - The 2025 Annual Meeting of Stockholders is scheduled for June 18, 2025, with a proposal to reduce the Board of Directors from six to five members and to consider two reverse stock split proposals to meet Nasdaq listing requirements [3] - The SYMON-II clinical study has been initiated, following the successful SYMON-I pilot study, which indicated that IL-6 levels could predict sepsis patient mortality [4] - The company aims to submit a 510(k) application for its Symphony IL-6 test to the FDA in Q4 2027, with potential approval as early as Q3 2028 [4] - Bluejay is collaborating with SanyoSeiko for manufacturing the Symphony analyzer and is redeveloping Symphony cartridges to address technical challenges [4] Financial Results - As of April 30, 2025, Bluejay had cash and cash equivalents of approximately $5.7 million and current liabilities of about $1.0 million [4] - The company reported losses of approximately $7.7 million for the fiscal year ended December 31, 2024, and $1.9 million for the fiscal quarter ended March 31, 2025 [4] - In April 2025, Bluejay raised approximately $3.8 million through Class C warrant exercises and new Class E warrants, with a goal to raise at least $30 million by the end of the 2027 fiscal year [4] Product and Clinical Study Information - The Symphony IL-6 Test is designed for sepsis triage and monitoring, providing results in about 20 minutes [5][7] - The SYMON Clinical Study Program includes SYMON-I and SYMON-II, with SYMON-I focusing on IL-6 levels related to mortality outcomes [6]

Core Viewpoint - Bluejay Diagnostics, Inc. has entered into an agreement with existing institutional investors to exercise warrants for common stock, raising approximately $3.7 million in gross proceeds at a reduced exercise price of $3.42 per share [1][2]. Company Overview - Bluejay Diagnostics, Inc. is a medical technology company focused on developing rapid diagnostics through its Symphony platform to enhance patient outcomes in critical care settings [1][5]. - The company's first product candidate is an IL-6 Test for sepsis, designed to deliver accurate results in about 20 minutes, aiding medical professionals in making timely treatment decisions [5]. Financial Transaction Details - Investors will receive new warrants to purchase an equal number of shares (1,085,106) at the same exercise price of $3.42, which are exercisable immediately and will expire in five years [2]. - The transaction was facilitated by Aegis Capital Corp. as the exclusive financial advisor, with legal counsel provided by Hogan Lovells US LLP for the company and Kaufman & Canoles, P.C. for Aegis Capital Corp. [4].